Gain Therapeutics, Inc. (GANX) Stock

Gain Therapeutics, Inc. (GANX) is a Healthcare stock trading at $1.87 (as of 2026-06-18), with a market capitalization of $83.18M and a trailing P/E of -3.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Gain Therapeutics, Inc. develops therapies for diseases associated with protein misfolding, with a focus on rare genetic disorders and neurological conditions. Using its Site-Directed Enzyme Enhancement approach, the company identifies small molecules that target allosteric sites on misfolded proteins and is developing structurally targeted allosteric regulator candidates for conditions including Morquio B, GM1 gangliosidosis, neuronopathic Gaucher disease, GBA1 Parkinson’s, Krabbe, and Mucopolysaccharidosis type 1.

Valuation — source: SEC EDGAR (first-party)
Price	$1.87
Market Cap	$83.18M
P/E Ratio	-3.2
EV / EBITDA	-3.3
Price / Book	5.72
Price / Sales	1453.24
DCF Value (model)	$-6.96
DCF Upside vs Price	-472.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$55180.00
Net Margin	-40354.3%
Return on Equity	-151.6%
Debt / Equity	0.03
Current Ratio	4.69

Valuation vs Sector & Industry
Stock P/E	-3.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-115.5%
vs Industry	-119.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	MARSHALL WACE, LLP ($3.43M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Gene Mack
Employees	23
Country	US
IPO Date	2021-03-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.